These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 36239554)

  • 1. New treatment strategies for human epidermal growth factor receptor 2-positive breast cancer in 2023.
    Banys-Paluchowski M; Krawczyk N; Stickeler E; Müller V; Fehm T
    Curr Opin Obstet Gynecol; 2023 Feb; 35(1):54-61. PubMed ID: 36239554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study.
    Curigliano G; Dunton K; Rosenlund M; Janek M; Cathcart J; Liu Y; Fasching PA; Iwata H
    Ann Oncol; 2023 Jul; 34(7):569-577. PubMed ID: 37179020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
    Hurvitz SA; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Egorov A; Liu Y; Cathcart J; Bako E; Tecson K; Verma S; Cortés J
    ESMO Open; 2024 May; 9(5):102924. PubMed ID: 38796287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment.
    Ji C; Li F; Yuan Y; Zhang H; Bian L; Zhang S; Wang T; Li J; Jiang Z
    Oncologist; 2023 Oct; 28(10):e859-e866. PubMed ID: 37218076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis.
    DeBusk K; Abeysinghe S; Vickers A; Nangia A; Bell J; Ike C; Forero-Torres A; Blahna MT
    Future Oncol; 2021 Nov; 17(33):4635-4647. PubMed ID: 34463120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic landscape of advanced HER2-positive breast cancer in 2022.
    Gupta R; Gupta S; Antonios B; Ghimire B; Jindal V; Deol J; Gaikazian S; Huben M; Anderson J; Stender M; Jaiyesimi I
    Med Oncol; 2022 Oct; 39(12):258. PubMed ID: 36224475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How we treat patients with metastatic HER2-positive breast cancer.
    Nader-Marta G; Martins-Branco D; de Azambuja E
    ESMO Open; 2022 Feb; 7(1):100343. PubMed ID: 34995893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic management of brain metastases in HER2+ breast cancer in 2022.
    Alder L; Sammons S; Van Swearingen AED; Anders CK
    Clin Adv Hematol Oncol; 2022 May; 20(5):325-336. PubMed ID: 35579591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives.
    Dormann C
    Breast Care (Basel); 2020 Dec; 15(6):570-578. PubMed ID: 33447230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort.
    Moinard-Butot F; Saint-Martin C; Pflumio C; Carton M; Jacot W; Cottu PH; Diéras V; Dalenc F; Goncalves A; Debled M; Patsouris A; Mouret-Reynier MA; Vanlemmens L; Leheurteur M; Emile G; Ferrero JM; Desmoulins I; Uwer L; Eymard JC; Cheaib B; Courtinard C; Bachelot T; Chevrot M; Petit T
    Breast; 2022 Jun; 63():54-60. PubMed ID: 35299035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective.
    Ferrario C; Christofides A; Joy AA; Laing K; Gelmon K; Brezden-Masley C
    Curr Oncol; 2022 Apr; 29(4):2720-2734. PubMed ID: 35448196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA.
    Wang J; Yi Y; Wan X; Zeng X; Peng Y; Tan C
    Adv Ther; 2022 Oct; 39(10):4583-4593. PubMed ID: 35943715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study.
    Conte B; Fabi A; Poggio F; Blondeaux E; Dellepiane C; D'Alonzo A; Buono G; Arpino G; Magri V; Naso G; Presti D; Mura S; Fontana A; Cognetti F; Molinelli C; Pastorino S; Bighin C; Miglietta L; Boccardo F; Lambertini M; Del Mastro L;
    Clin Breast Cancer; 2020 Apr; 20(2):e181-e187. PubMed ID: 31735691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model.
    Pourjamal N; Yazdi N; Halme A; Joncour VL; Laakkonen P; Saharinen P; Joensuu H; Barok M
    Clin Exp Metastasis; 2024 Apr; 41(2):91-102. PubMed ID: 38367127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.
    Hamilton EP; Kaklamani V; Falkson C; Vidal GA; Ward PJ; Patre M; Chui SY; Rotmensch J; Gupta K; Molinero L; Li Y; Emens LA
    Clin Breast Cancer; 2021 Dec; 21(6):539-551. PubMed ID: 34154926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
    Murthy RK; Loi S; Okines A; Paplomata E; Hamilton E; Hurvitz SA; Lin NU; Borges V; Abramson V; Anders C; Bedard PL; Oliveira M; Jakobsen E; Bachelot T; Shachar SS; Müller V; Braga S; Duhoux FP; Greil R; Cameron D; Carey LA; Curigliano G; Gelmon K; Hortobagyi G; Krop I; Loibl S; Pegram M; Slamon D; Palanca-Wessels MC; Walker L; Feng W; Winer EP
    N Engl J Med; 2020 Feb; 382(7):597-609. PubMed ID: 31825569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.
    Borges VF; Ferrario C; Aucoin N; Falkson C; Khan Q; Krop I; Welch S; Conlin A; Chaves J; Bedard PL; Chamberlain M; Gray T; Vo A; Hamilton E
    JAMA Oncol; 2018 Sep; 4(9):1214-1220. PubMed ID: 29955792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland.
    Paulissen JHJ; Seddik AH; Dunton KJ; Livings CJ; van Hulst M; Postma MJ; de Jong LA; Freriks RD
    Eur J Health Econ; 2024 Jun; 25(4):689-699. PubMed ID: 37486557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis.
    Zhu Y; Liu K; Wang M; Wang K; Zhu H
    Breast; 2022 Dec; 66():191-198. PubMed ID: 36327624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
    Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP;
    J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.